Original Article
  

Altered Expression of MicroRNAs Following Chronic Allograft Dysfunction with Interstitial Fibrosis and Tubular Atrophy

Abstract

Chronic allograft dysfunction (CAD) remains the major cause of renal transplant loss and characterized by interstitial fibrosis and tubular atrophy (IFTA). MicroRNAs (miRNAs) are implicated in many biological processes as well as innate and adaptive immune responses. We aimed to investigate whether CAD with IFTA is associated with differential expression of miR-142-5p, miR-142-3p and miR-211 within biopsy and peripheral blood mononuclear cell (PBMC) samples and whether expression of miRNAs are diagnostic for CAD with IFTA and predicts renal allograft function. In this study, biopsy and PBMC samples of 16 CAD with IFTA and 17 normal allografts (NA) were collected. Using Taqman MicroRNA Assays the expression levels of miR-142-5p, miR-142-3p and miR-211 were determined in two groups. Our results showed that miR-142-5p and miR–142-3p were significantly (p<0.0001) up-regulated and miR-211 was significantly (p<0.0001) down-regulated in renal allograft tissues of CAD with IFTA compared with NA recipients. Moreover, miR-142-3p and miR-211 were significantly (p<0.0001) up-regulated and down-regulated respectively in PBMC samples of CAD with IFTA. According to the ROC curve analysis, miR-142-5p in biopsy samples, but miR-142-3p and miR-211 both in biopsy and PBMC samples could be used as a diagnostic biomarker of CAD with IFTA and a prediction factor of allograft function. In this study, miRNAs were differentially expressed in the kidney allograft biopsy and simultaneously in PBMC samples of patients with CAD with IFTA. We suggest that the expression of miRNAs in PBMC might be used for monitoring the post transplantation and also as potential non-invasive biomarkers of kidney graft function and CAD with IFTA.

1. Langone AJ, Helderman JH. Disparity between solid- organ supply and demand. N Engl J Med 2003;349(7):704-6.

2. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005;16(10):3015-26.

3. Ting YT, Coates PT, Walker RJ, McLellan AD. Urinary tubular biomarkers as potential early predictors of renal allograft rejection. Nephrology (Carlton) 2012; 17(1):11-6.

4. Ahmad I. Biopsy of the transplanted kidney. Semin Intervent Radiol 2004; 21(4):275-81.

5. Soltaninejad E, Nicknam MH, Nafar M, Ahmadpoor P, Pourrezagholi F, Sharbafi MH, et al.,Differential expression of microRNAs in renal transplant patients with acute T-cell mediated rejection. Transpl Immunol 2015;33(1):1-6

6. Furness PN, Taub N. International variation in the interpretation of renal transplant biopsies: report of the CERTPAP Project. Kidney Int 2001; 60(5):1998-2012.

7. Sorof JM, Vartanian RK, Olson JL, Tomlanovich SJ, Vincenti FG, Amend WJ. Histopathological concordance of paired renal allograft biopsy cores. Effect on the diagnosis and management of acute rejection. Transplantation 1995; 60(11):1215-9.

8. Gillespie A, Lee IJ. Biomarkers in renal transplantation.Biomark Med 2008; 2(6):603-12.

9. Shyu AB, Wilkinson MF, van Hoof A. Messenger RNA regulation: to translate or to degrade. EMBO J 2008;27(3):471-81.

10. Ho J, Kreidberg JA. The long and short of microRNAs in the kidney. J Am Soc Nephrol 2012; 23(3):400-4.

11. Ma L, Qu L. The function of microRNAs in renal development and pathophysiology. J Genet Genomics 2013; 40(4):143-52.

12. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006; 20(5):515-24.

13. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 2011; 80(2):193-208.

14. Tijsen AJ, Pinto YM, Creemers EE. Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases. Am J Physiol Heart Circ Physiol 2012;303(9):H1085-95.

15. Anglicheau D, Sharma VK, Ding R, Hummel A, Snopkowski C, Dadhania D, et al. MicroRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci U S A 2009; 106(13):5330-5.

16. Sui W, Dai Y, Huang Y, Lan H, Yan Q, Huang H.Microarray analysis of MicroRNA expression in acute rejection after renal transplantation. Transpl Immunol 2008; 19(1):81-5.

17. Ben-Dov IZ, Muthukumar T, Morozov P, Mueller FB, Tuschl T, Suthanthiran M. MicroRNA sequence profiles of human kidney allografts with or without tubulointerstitial fibrosis. Transplantation 2012;94(11):1086-94.

18. Glowacki F, Savary G, Gnemmi V, Buob D, Van der Hauwaert C, Lo-Guidice JM, et al. Increased circulating miR-21 levels are associated with kidney fibrosis. PLoS One 2013; 8(2):e58014.

19. Scian MJ, Maluf DG, David KG, Archer KJ, Suh JL, Wolen AR, et al. MicroRNA Profiles in Allograft Tissues and Paired Urines Associate With Chronic Allograft Dysfunction With IF/TA. Am J Transplant 2011;11(10):2110-22.

20. Danger R, Paul C, Giral M, Lavault A, Foucher Y, Degauque N, et al. Expression of miR-142-5p in peripheral blood mononuclear cells from renal transplant patients with chronic antibody-mediated rejection. PLoS One 2013; 8(4):e60702.

21. Danger R, Pallier A, Giral M, Martínez-Llordella M, Lozano JJ, Degauque N, et al. Upregulation of miR-142-3p in peripheral blood mononuclear cells of operationally tolerant patients with a renal transplant. J Am Soc Nephrol 2012; 23(4):597-606.

22. Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10(3):464-71.

23. Livak KJ, Schmittgen TD. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25(4):402-8.

24. Ahmad I. Biopsy of the transplanted kidney. in Seminars in interventional radiology. Semin Intervent Radiol 2004;21(4):275-81.

25. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al.Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 2008. 18(10): p. 997-1006.

26. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105(30):10513-8.

27. Meier-Kriesche HU, Ojo AO, Hanson JA, Cibrik DM, Punch JD, Leichtman AB et al. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 2000; 70(7):1098-100.

28. Moreso F, Ibernon M, Gomà M, Carrera M, Fulladosa X, Hueso M, et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006;6(4):747-52.

29. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007;129(7):1401-14.

30. Huang B, Zhao J, Lei Z, Shen S, Li D, Shen GX, et al. miR-142-3p restricts cAMP production in CD4+CD25- T cells and CD4+CD25+ TREG cells by targeting AC9 mRNA. EMBO Rep 2009; 10(2):180-5.

31. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56(11):1733-41.

Files
IssueVol 14, No 6 (2015) QRcode
SectionOriginal Article(s)
Keywords
Biomarker Chronic allograft dysfunction IFTA MicroRNA Renal transplantation
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Soltaninejad E, Nicknam MH, Nafar M, Sharbafi MH, Keshavarz Shahbaz S, Barabadi M, Yekaninejad MS, Bahrami T, Ahmadpoor P, Amirzargar A. Altered Expression of MicroRNAs Following Chronic Allograft Dysfunction with Interstitial Fibrosis and Tubular Atrophy. Iran J Allergy Asthma Immunol. 2015;14(6):615-623.